Reporting the study populations of clinical trials. Clear transmission or static on the line? (Q53510768)

15 May 2018

title

Reporting the study populations of clinical trials. Clear transmission or static on the line? (English)

1 reference

15 May 2018

author

Charles Weijer

series ordinal

2

1 reference

15 May 2018

author name string

Shapiro SH

series ordinal

1

1 reference

15 May 2018

Freedman B

series ordinal

3

1 reference

15 May 2018

publication date

1 October 2000

1 reference

15 May 2018

Journal of Clinical Epidemiology

published in

1 reference

15 May 2018

volume

53

1 reference

15 May 2018

issue

10

1 reference

15 May 2018

page(s)

973-979

1 reference

15 May 2018

Shattuck Lecture--misconduct in medical research

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

The existence of publication bias and risk factors for its occurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Meta-analysis: State-of-the-Science

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Guidelines for publishing papers on cancer clinical trials: responsibilities of editors and authors.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Is the published literature a reliable guide for deciding between alternative treatments for patients with early cervical cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

A quality assessment of randomized control trials of primary treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Reporting on methods in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Of clinical alerts and peer review

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Design, methods, and conduct of the Optic Neuritis Treatment Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid Stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Corticosteroid Treatment of Acute Optic Neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Point/Counterpoint. NCI Clinical Alert policy. Sometimes a great notion

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Clinical alerts: Broder discusses pros and cons on the record

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Eligibility and extrapolation in cancer clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Toward a duty to report clinical trials accurately: the clinical alert and beyond.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Why do we need some large, simple randomized trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2800%2900227-4

7 January 2021

10.1016/S0895-4356(00)00227-4

Identifiers

DOI

1 reference

15 May 2018

release_qwk5tprsynhldleuxfmawcol5a

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qwk5tprsynhldleuxfmawcol5a

24 November 2022

mapped directly with Wikidata item

1 reference

15 May 2018